The atypical antipsychotic, olanzapine, potentiates ghrelin-induced receptor signaling: An in vitro study with cells expressing cloned human growth hormone secretagogue receptor

Neuropeptides
Keita TagamiYasuhito Uezono

Abstract

The growth hormone secretagogue receptor (GHS-R) belongs to Gαq-coupled G protein-coupled receptor (GPCR) that mediates growth hormone release, food intake, appetite, glucose metabolism and body composition. Ghrelin has been identified as an endogenous ligand for GHS-R, and it is the only orexigenic peptide found in the peripheral organs. Olanzapine, an atypical antipsychotic agent that binds to and inhibits the activation of GPCR for several neurotransmitters, has metabolic side effects such as excessive appetite and weight gain. Recently, studies have revealed that the orexigenic mechanism of olanzapine is mediated via GHS-R signaling, although the precise mechanisms have not been clarified. In this study, we investigated the effect of olanzapine on ghrelin-mediated GHS-R signaling by using an electrical impedance-based receptor biosensor assay system (CellKey™). Olanzapine at concentrations of 10(-7) and 10(-6)mol/L enhanced ghrelin-induced (10(-10)-10(-8)mol/L) GHS-R activation. A Ca(2+) imaging assay revealed that olanzapine (10(-7) and 10(-6)mol/L) enhanced ghrelin (10(-7) M)-induced GHS-R activity. In contrast, haloperidol (an antipsychotic agent) failed to enhance this ghrelin-mediated GHS-R activation, as demonstrated ...Continue Reading

References

Feb 1, 1996·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·F P BymasterD T Wong
Oct 23, 1997·Endocrine Reviews·R G SmithA A Patchett
Aug 26, 1998·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·H J AndreyevD Cunningham
Jun 9, 1999·The American Journal of Psychiatry·S K OberA Rusterholtz
Mar 4, 2000·Proceedings of the National Academy of Sciences of the United States of America·K L PierceR J Lefkowitz
May 25, 2002·The New England Journal of Medicine·David E CummingsJonathan Q Purnell
Aug 13, 2002·Hematology/oncology Clinics of North America·Florian Strasser, Eduardo D Bruera
Jul 3, 2003·The Journal of Physiology·Kazunori FujinoMineko Fujimiya
Jun 8, 2004·The Journal of Clinical Endocrinology and Metabolism·Nicola M NearyStephen R Bloom
Sep 11, 2004·Psychoneuroendocrinology·Mari MurashitaTsukasa Koyama
Dec 22, 2004·Journal of General Internal Medicine·Wildon R FarwellWilliam M Tierney
Aug 12, 2006·Journal of Molecular Endocrinology·H Douglas FallsWiweka Kaszubska
Jan 1, 2008·Schizophrenia Bulletin·Othman SentissiMarie-France Poirier
Jun 27, 2008·Progress in Neuro-psychopharmacology & Biological Psychiatry·Ayşen Esen-DanaciNesrin Ozlen
Feb 6, 2009·The Journal of Clinical Psychiatry·Hiroshi UjikeShigetoshi Kuroda
Mar 27, 2009·Schizophrenia Research·Bruce ParsonsCynthia Siu
Sep 17, 2009·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Rudolph M Navari, Marie C Brenner
Dec 30, 2009·Pharmacological Reviews·Chih-Yen ChenAkio Inui
Jan 21, 2010·Assay and Drug Development Technologies·Matthew F PetersClay W Scott
Jul 6, 2010·Drug Discovery Today·Clay W Scott, Matthew F Peters
Aug 6, 2010·Journal of the Chinese Medical Association : JCMA·Chih-Yen ChenShou-Dong Lee
Feb 8, 2011·The Lancet Oncology·Kenneth FearonVickie E Baracos
Dec 3, 2011·CNS Drugs·James L RoerigJames E Mitchell
May 29, 2012·Current Pharmaceutical Design·Yasuhito UezonoKiyoshi Terawaki
May 29, 2012·Current Pharmaceutical Design·Toshihiko YadaKoji Yakabi
Aug 8, 2012·Archives of General Psychiatry·Jose MathewsDeanna M Barch
Aug 18, 2012·European Journal of Endocrinology·Patric J D DelhantyAart J van der Lely
Oct 20, 2012·Expert Opinion on Biological Therapy·Josep M Argilés, Britta Stemmler
Aug 21, 2013·Psychoneuroendocrinology·Qingsheng ZhangXu-Feng Huang
Dec 20, 2013·Journal of Molecular Endocrinology·Hiroyuki KaiyaMikiya Miyazato

❮ Previous
Next ❯

Citations

Sep 12, 2017·Journal of Psychopharmacology·Gavin P Reynolds, Olga O McGowan
Nov 15, 2017·Nordic Journal of Psychiatry·Özgür Korhan TunçelEbru Kaynar Tunçel
Aug 15, 2017·Frontiers in Neuroscience·Zachary FreybergJacob S Ballon
Aug 23, 2020·Medical Sciences : Open Access Journal·Jessie Rice, Ujjwal Ramtekkar
Nov 28, 2020·Current Treatment Options in Oncology·Mellar P Davis, Gareth J Sanger
May 15, 2021·Physiology & Behavior·Kimberly R Smith, Timothy H Moran
Jan 4, 2022·Journal of Palliative Medicine·Tomoko KawaiKazue Ota

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Asprosin

Asprosin is a fasting-induced hormone produced in the white adipose tissue to stimulate the hepatic release of glucose into the bloodstream. Discover the latest research on this protein hormone here.